1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia

Dalbavancin is a lipoglycopeptide with a long half-life that allows infrequent dosing. It is indicated for the treatment of acute bacterial skin and skin structure infections caused by susceptible organisms, including Staphylococcus aureus and methicillin-resistant S. aureus (MRSA). Although this agent has been used off-label clinically, there are minimal data in infections outside the current ...

Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults

The treatment of MRSA skin and soft tissue infections in adults will be reviewed here. The treatment of invasive MRSA infections, the mechanisms of antibiotic resistance, epidemiology of MRSA infection, and general issues related to skin and soft tissue infections are discussed separately. (See "Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults" and "Microbi...

Staphylococcus aureus bloodstream infections: definitions and treatment.

Bacteremia caused by Staphylococcus aureus is a serious infection associated with high morbidity and mortality and often results in metastatic infections such as infective endocarditis, which have a negative impact on patient outcomes. We review the importance of the use of precise definitions of uncomplicated bacteremia and complicated bacteremia and present a case study to highlight the need ...

Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections

Daptomycin is a lipopeptide antibiotic with a unique mechanism of action on Gram-positive bacteria. It is approved for treatment of skin and soft-tissue infections with Gram-positive bacteria, bacteraemia and right-sided infective endocarditis caused by Staphylococcus aureus. Diminishing susceptibility of S. aureus to daptomycin during treatment of complicated infections and clinical failure ha...

Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.